<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   GABA-B agonist (baclofen, phenibut) poisoning and withdrawal
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       GABA-B agonist (baclofen, phenibut) poisoning and withdrawal
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        GABA-B agonist (baclofen, phenibut) poisoning and withdrawal
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kavita M Babu, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Erica L Liebelt, MD, FACMT
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1543406730">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         is used for the management of muscle spasticity, dystonia, substance use disorders, and hiccups. Baclofen is sometimes delivered as a continuous infusion via intrathecal pump; malfunction can lead to withdrawal or, less commonly, overdose. Phenibut was developed as an anxiolytic and cognition enhancer (nootropic). It is a controlled substance in some countries. Although it can be purchased from internet vendors, it has not been reviewed by the US Food and Drug Administration and thus has not been approved for any medical indication or use as a supplement. Both are recreationally misused. These medications can cause lethargy and respiratory depression or paradoxical agitation in overdose. Sudden cessation of baclofen or phenibut after chronic use can manifest a life-threatening withdrawal syndrome that requires aggressive treatment.
        </p>
        <p>
         This topic will discuss the evaluation and management of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         and phenibut poisoning and withdrawal. A summary table to facilitate emergency management is provided  (
         <a class="graphic graphic_table graphicRef143115" href="/z/d/graphic/143115.html" rel="external">
          table 1
         </a>
         ). The therapeutic use of baclofen and the general evaluation and management of the poisoned patient are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118855.html" rel="external">
          "Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/126971.html" rel="external">
          "High-risk dietary supplements: Patient evaluation and counseling"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">
          "Initial management of the critically ill adult with an unknown overdose"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2732874023">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baclofen
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         Approximately 5000
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         exposures are reported annually to United States regional poison control centers, producing between 2 and 12 deaths yearly [
         <a href="#rid1">
          1-5
         </a>
         ]. In 2020, baclofen was reported to United States regional poison control centers as the sole agent in overdoses in 2112 cases, including more than 1100 intentional exposures, nearly 700 unintentional exposures, and 110 adverse medication reactions [
         <a href="#rid2">
          2
         </a>
         ]. In baclofen-associated fatalities, frequent co-ingestants included opioids, benzodiazepines, and
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenibut
         </strong>
         – Among 1320 exposure calls involving phenibut to United States poison control centers from 2009 to 2019, there were three fatalities reported, two of which involved a co-ingestant [
         <a href="#rid6">
          6
         </a>
         ]. The number of exposures rose sharply between 2015 and 2018, possibly due to increased marketing, popularity, and availability.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2437785531">
         <span class="h1">
          PHARMACOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         and phenibut are structurally similar to gamma aminobutyric acid (GABA), the predominant inhibitory neurotransmitter. They are agonists at GABA-B receptors, which are ubiquitously located both pre- and postsynaptically in the central nervous system (CNS). GABA-B receptors are G protein-coupled receptors; depending on location, activation can inhibit adenylyl cyclase, gate ion channels, or open G protein-gated inwardly rectifying potassium channels (and hyperpolarize neuronal membranes) [
         <a href="#rid7">
          7
         </a>
         ]. GABA-B receptors are implicated in many disease processes, including epilepsy, anxiety, depression, schizophrenia, obsessive-compulsive disorder, addiction, and pain. In contrast, the GABA-A receptor is a ligand-gated chloride channel located primarily postsynaptically in the CNS and has binding sites for many sedative-hypnotic agents (eg, benzodiazepines, barbiturates,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         ) in addition to GABA [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baclofen
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         reduces muscle spasticity by acting on the spinal cord. It is occasionally delivered in low doses (25 to 1000 mcg/day) intrathecally via a surgically implanted, computer-programmed infusion pump, which achieves high spinal concentrations and good spasmolytic effects without adverse effects (eg, sedation) associated with higher oral doses [
         <a href="#rid9">
          9
         </a>
         ]. Pump malfunction is a rare complication that can cause baclofen withdrawal or overdose. Other complications of intrathecal baclofen pumps are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/118855.html" rel="external">
          "Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues", section on 'Intrathecal baclofen'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4839.html" rel="external">
          "Chronic complications of spinal cord injury and disease", section on 'Intrathecal baclofen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenibut
         </strong>
         –
         <strong>
         </strong>
         Phenibut (beta-phenyl-gamma-aminobutyric acid) was developed in Russia in the 1960s for anxiolysis and as a cognition enhancer (nootropic) [
         <a href="#rid10">
          10
         </a>
         ]. It is approved for medical use in Russia and various Eastern European countries, can be purchased from internet vendors in the United States, and is found in some cognitive enhancement supplements [
         <a href="#rid11">
          11,12
         </a>
         ]. In addition to acting as a GABA-B
         <sub>
         </sub>
         receptor agonist, phenibut may share a mechanism with
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         in binding to the alpha-2-delta subunit of the voltage-dependent calcium channel. The gabapentin-like action inhibits presynaptic calcium influx and release of excitatory neurotransmitters [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Phenibut users report dose-dependent effects with physical and mental stimulation, wakefulness, and euphoria at lower doses; at higher doses, sedation, anxiolysis, and muscle relaxation predominate [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Daily use of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut can lead to the development of tolerance, dependence, and life-threatening withdrawal symptoms with abrupt cessation of therapy [
         <a href="#rid12">
          12,14,15
         </a>
         ]. (See
         <a class="local">
          'Withdrawal syndromes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1890143908">
         <span class="h1">
          PHARMACOKINETICS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral
         </strong>
         <strong>
          baclofen
         </strong>
         <strong>
          administration
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Absorption
         </strong>
         –
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         is rapidly absorbed after oral administration, reaching peak concentrations within one to three hours [
         <a href="#rid16">
          16,17
         </a>
         ]. Bioavailability is high (&gt;70 percent) and similar between oral tablets and suspension [
         <a href="#rid16">
          16,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Distribution
         </strong>
         –
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         has low plasma protein binding and a low (&lt;1.2 L/kg) volume of distribution [
         <a href="#rid19">
          19-21
         </a>
         ]. Baclofen is lipophilic and rapidly distributes into cerebral spinal fluid (CSF). However, only a small portion of baclofen crosses into the CSF; thus, large oral doses or direct intrathecal delivery are needed to achieve a therapeutic effect [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Metabolism
         </strong>
         – Approximately 15 percent of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         is hepatically deaminated [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Elimination
         </strong>
         –
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         is mostly eliminated unchanged by the kidneys (70 percent) [
         <a href="#rid12">
          12,19,20
         </a>
         ]. The elimination half-life is two to seven hours in therapeutic dosing with normal kidney function, but can be significantly prolonged in the setting of overdose or kidney impairment [
         <a href="#rid20">
          20,23,24
         </a>
         ]. The elimination half-life lengthens from 10 hours in overdose with normal kidney function to 80 hours in therapeutic dosing in patients with stage IV or V chronic kidney disease, with large inter-individual variability [
         <a href="#rid19">
          19,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A renal dosing adjustment for
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         is required to prevent toxicity during therapeutic dosing, given primarily renal elimination [
         <a href="#rid25">
          25
         </a>
         ]. Patients with chronic kidney disease can develop toxicity within three days of starting baclofen [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intrathecal
         </strong>
         <strong>
          baclofen
         </strong>
         <strong>
          administration
         </strong>
         – After an intrathecal
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         bolus, the onset of action is approximately 30 to 60 minutes, with a peak action and duration of four and eight hours, respectively. During continuous infusion, the maximal effect occurs at 24 to 48 hours. Plasma baclofen concentrations are expected to be low (&lt;5 ng/mL) in adults; in a cohort of six pediatric patients, concentrations were near or less than 10 ng/mL [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Elimination likely occurs due to CSF turnover. After a single intrathecal bolus, the CSF elimination half-life was 1.5 hours during the first four hours then two to five hours afterward, but it shows large inter-individual variability [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenibut
         </strong>
         – There is little published regarding the pharmacokinetics of phenibut [
         <a href="#rid10">
          10
         </a>
         ]. It is mostly eliminated unchanged by the kidneys (65 percent). The elimination half-life is approximately six hours in therapeutic dosing with normal kidney function, but can be significantly prolonged in the setting of overdose or kidney impairment [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1864549218">
         <span class="h1">
          CLINICAL FEATURES OF OVERDOSE
         </span>
        </p>
        <p class="headingAnchor" id="H3855741529">
         <span class="h2">
          Overview and vital sign abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         and phenibut overdose cause a wide range of manifestations that typically involve the central nervous system (CNS). Common vital sign abnormalities include hypothermia, hypoventilation, bradycardia, and hypotension.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baclofen
         </strong>
         – Mild symptoms following
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         overdose include nausea, vomiting, and somnolence. More severe manifestations include myoclonus, hypotonia, hypothermia, bradycardia, hypotension, respiratory depression/failure, seizure, and/or coma. One-third to one-half of patients with baclofen toxicity have been reported to require tracheal intubation and mechanical ventilation [
         <a href="#rid19">
          19
         </a>
         ]. Marked hypothermia with the presence of Osborn waves has been reported after baclofen ingestion [
         <a href="#rid29">
          29
         </a>
         ]. Both mydriasis and miosis have been reported following baclofen overdose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intrathecal pump malfunction causing
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         overdose has been reported, although pump malfunction more frequently results in withdrawal. Intrathecal baclofen overdose can rapidly cause severe toxicity similar to oral overdose; the hypotonia often progresses in a rostral direction [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenibut
         </strong>
         – Toxicity ranges from nausea, vomiting, and sedation to severe and life-threatening respiratory depression. In a systematic review, almost half of patients who presented with phenibut toxicity required tracheal intubation [
         <a href="#rid12">
          12
         </a>
         ]. Most patients (90 percent) develop altered mental status (either sedation or agitation/psychosis) and some (&lt;15 percent) will develop disordered movements. Phenibut ingestion can cause hypothermia and bradycardia but can also produce paradoxical diaphoresis, tachycardia, and/or hypertension [
         <a href="#rid6">
          6,12,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2980481447">
         <span class="h2">
          CNS depression, movement disorders
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baclofen
         </strong>
         –
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         toxicity causes central nervous system (CNS) depression ranging from sedation to coma, frequently requiring tracheal intubation for airway protection. In a case series of 23 patients presenting after baclofen overdose, eight required mechanical ventilation; of these patients, seven had a reported ingestion greater than 200 mg [
         <a href="#rid33">
          33
         </a>
         ]. A common manifestation of phenibut misuse and ingestion is CNS depression, often described as drowsiness, lethargy, confusion, and occasionally coma [
         <a href="#rid6">
          6,32,34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Severe
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         toxicity can mimic anoxic brain injury or brain death with loss of brain stem reflexes and burst suppression pattern on electroencephalogram [
         <a href="#rid36">
          36-40
         </a>
         ]. Patients with baclofen overdose have nearly undergone premature organ harvest and cessation of life-supporting treatment [
         <a href="#rid39">
          39
         </a>
         ]. Although most patients improve within 48 to 72 hours, baclofen toxicity can last longer than five elimination half-lives, which is the commonly used criteria for establishing brain death during drug intoxication  (
         <a class="graphic graphic_table graphicRef142111" href="/z/d/graphic/142111.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4831.html" rel="external">
          "Diagnosis of brain death", section on 'Brain death mimics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         can cause myoclonus, hypotonia, hyporeflexia, and/or areflexia [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenibut
         </strong>
         – Phenibut toxicity can produce various movement disorders, including tremor, myoclonus, dystonia, and rigidity [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H321086762">
         <span class="h2">
          Agitation, psychosis, seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         and phenibut, in either misuse or overdose, can produce paradoxical agitation; erratic behavior, delirium, paranoia, psychosis, and auditory and visual hallucinations have been reported [
         <a href="#rid6">
          6,32,34,42-45
         </a>
         ]. Occasionally, the agitation is sufficiently severe that tracheal intubation is required to provide adequate pharmacologic sedation [
         <a href="#rid32">
          32,43
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         overdose can cause single or multiple seizures [
         <a href="#rid46">
          46
         </a>
         ]. In a case series of 23 patients presenting after baclofen overdose, four had witnessed or reported seizures [
         <a href="#rid33">
          33
         </a>
         ]. All four patients with seizures had a reported ingestion of greater than 200 mg. Isolated seizures have been reported following overdose of phenibut [
         <a href="#rid6">
          6,32
         </a>
         ].
        </p>
        <p>
         Since GABA is an inhibitory neurotransmitter, it is counterintuitive that overdose of a GABA-agonist would cause psychomotor agitation, psychosis, and seizures. However,
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         and phenibut overdose can actually decrease CNS inhibitory tone depending on the location (presynaptic versus postsynaptic) of the GABA-B receptor, distinguishing their toxicity from CNS depression caused by GABA-A agonist overdose [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2109153895">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other suspected overdoses, the evaluation of a patient with suspected
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut overdose involves collecting available history, performing a targeted physical examination, and obtaining relevant ancillary studies.
        </p>
        <p class="headingAnchor" id="H912436163">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are key elements of a clinical history in a suspected
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut overdose:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reasons to suspect overdose (eg, suicide note, witnessed, reported to bystanders)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Time of ingestion or last dose
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intent behind use (self-harm versus misuse)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of intrathecal pump (if
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         is suspected) and any recent pump manipulation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspected co-ingestants
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Names of other accessible medications
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Last time patient was seen without signs of toxicity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior history of self-harm attempts
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of substance use disorder, chronic kidney disease, or seizures
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3582937777">
         <span class="h2">
          Examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         We perform a targeted physical examination assessing vital signs, mental status, ability to protect airway, focal neurologic deficits, muscle tone, clonus, evidence of self-injury, and presence of specific toxidromes  (
         <a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">
          table 3
         </a>
         ). Patients with an unknown downtime should be evaluated for signs of compartment syndrome or traumatic myositis (eg, palpation of muscle compartments, including paraspinal and gluteal muscles).
        </p>
        <p>
         If the patient has an intrathecal pump, listen for an audible low battery/low reservoir volume alarm and inspect the surrounding tissue for a fluid collection. If a history cannot be obtained but the patient is suspected to be taking
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         , the anterior abdominal wall should be examined for an implanted device.
        </p>
        <p class="headingAnchor" id="H1633207316">
         <span class="h2">
          Laboratory studies and electrocardiograms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine laboratory and diagnostic testing of the patient with somnolence, including when
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut ingestion is suspected, is aimed at excluding other diagnoses and includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fingerstick blood glucose to rule out hypoglycemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum chemistries, creatinine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , salicylate, and ethanol concentrations to rule out these common co-ingestions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram (ECG) to screen for poisoning by drugs that affect the QRS or QTc intervals
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy test in females of childbearing age
        </p>
        <p>
        </p>
        <p>
         We obtain additional tests based upon historical and clinical findings. In a patient with a fever, in addition to obtaining studies to identify a source of infection (eg, urinalysis, chest radiograph), we also obtain creatine kinase, liver enzymes, and coagulation studies as these can be elevated if the patient has a severe withdrawal syndrome. (See
         <a class="local">
          'Withdrawal syndromes'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         or phenibut serum concentrations are not useful in the evaluation and management of the somnolent patient, even when an ingestion is suspected. These assays are not routinely available in the emergency setting and do not aid in acute management due to long turnaround times. Serum concentrations may be helpful confirmatory forensic tests (eg, pediatric patient with altered mental status in whom poisoning is suspected) or when a brain death declaration is considered in a patient with suspected baclofen overdose [
         <a href="#rid39">
          39
         </a>
         ]. When obtained, concentrations correlate with duration of mechanical ventilation [
         <a href="#rid47">
          47
         </a>
         ]. Serum concentration can also be helpful in excluding baclofen or phenibut poisoning as the etiology of unexplained prolonged coma. A therapeutic anti-spasticity serum baclofen concentration is 0.08 to 0.4 mg/L [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4166098152">
         <span class="h2">
          Patients with an intrathecal baclofen pump
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a patient with a
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         pump and concerns for toxicity or withdrawal, the clinician who manages the pump should be contacted. In a patient with signs of baclofen toxicity, the pump may need interrogation to ensure active dosing is consistent with the prescribed dosing and to check the pump’s residual volume [
         <a href="#rid30">
          30
         </a>
         ]. Premature reservoir emptying may not trigger the pump’s low reservoir volume alarm, which is often based on calculated remaining volume instead of actual measured volume.
        </p>
        <p>
         In a patient with signs of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         withdrawal, pump interrogation may reveal rotor stall, programming error, or other issues. Pump interrogation alone does not confirm proper function. If interrogation does not identify malfunction, confirming the pump reservoir volume and/or diagnostic aspiration of the catheter access port may be required and should only be performed by clinicians experienced with these procedures [
         <a href="#rid30">
          30
         </a>
         ]. If the catheter is radiopaque, radiographs (typically abdominal anteroposterior and lumbar/thoracic spine lateral) may identify disconnection, fracture, or migration from the spinal canal. Development of tolerance to baclofen should be a diagnosis of exclusion after the pump has been thoroughly evaluated. A full discussion on evaluation of baclofen pump malfunction is beyond the scope of this topic.
        </p>
        <p class="headingAnchor" id="H844059851">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         or phenibut poisoning is a clinical diagnosis that should be suspected in a somnolent patient known to take one of these agents and/or with a corroborating history (eg, report of ingestion) or who has an implanted intrathecal pump. In the absence of clear corroborating history, poisoning should be considered a diagnosis of exclusion. Non-toxicologic and other toxicologic etiologies must be ruled out, especially conditions in which diagnostic delay will hold up critical interventions and definitive care.
        </p>
        <p class="headingAnchor" id="H753168325">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         or phenibut poisoning can produce either a sedative-hypnotic toxidrome characterized by depressed mental status or delirium and agitation  (
         <a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">
          table 3
         </a>
         ). In any suspected ingestion when the patient cannot provide a history, an exploration of alternative sources of information is warranted, including but not exclusive to emergency medical services, family members, pill bottles when available, medical records, and pharmacy information. Unless the diagnosis of baclofen or phenibut poisoning is obvious, other life-threatening non-toxicologic causes must be investigated.
        </p>
        <p>
         The differential diagnosis varies according to the primary clinical features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system (CNS) depression
         </strong>
         – Sedation and coma  (
         <a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">
          table 4
         </a>
         ) are found in a wide range of medical and toxicologic conditions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypoglycemia must be excluded in every patient with altered mental status, even if
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut poisoning is suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ethanol and
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         intoxication, which can be assessed by obtaining serum concentrations. (See
         <a class="medical medical_review" href="/z/d/html/333.html" rel="external">
          "Ethanol intoxication in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">
          "Ethanol intoxication in children: Clinical features, evaluation, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13844.html" rel="external">
          "Barbiturate (phenobarbital) poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         , benzodiazepine,
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         ,
         <a class="drug drug_general" data-topicid="10126" href="/z/d/drug information/10126.html" rel="external">
          zopiclone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         are examples of commonly misused sedatives that can only be excluded by history. (See
         <a class="medical medical_review" href="/z/d/html/314.html" rel="external">
          "Benzodiazepine poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139762.html" rel="external">
          "Gabapentinoid poisoning and withdrawal"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gamma hydroxybutyrate (GHB) intoxication, which often manifests severe CNS depression followed by abrupt awakening. GHB intoxication is difficult to distinguish from other causes of obtundation without a clear history. (See
         <a class="medical medical_review" href="/z/d/html/307.html" rel="external">
          "Gamma hydroxybutyrate (GHB) intoxication"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Atypical antipsychotic agents (eg,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ), which are commonly misused and intentionally ingested, can cause sedation but also miosis and anticholinergic toxicity. (See
         <a class="medical medical_review" href="/z/d/html/304.html" rel="external">
          "Second-generation (atypical) antipsychotic medication poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A patient with partial improvement in mental status following
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         administration may have an opioid co-ingestion. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">
          "Opioid intoxication in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any focal neurologic findings or seizures raise concern for a CNS process such as stroke, intracranial hemorrhage, or encephalitis. (See
         <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">
          "Overview of the evaluation of stroke"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agitation, delirium, confusion
         </strong>
         –
         <strong>
         </strong>
         These are found in a wide range of medical and toxicologic conditions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anticholinergic poisoning typically causes an agitated delirium with tachycardia, dry lips and axilla, and mumbling speech. (See
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         .)
         <strong>
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The mnemonic FIND ME (functional [ie, psychiatric], infectious, neurologic, drugs, metabolic, endocrine) may be helpful to organize a diagnostic search for the etiology of delirium and agitation  (
         <a class="graphic graphic_table graphicRef59893" href="/z/d/graphic/59893.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A history of trauma or evidence of injuries should prompt obtaining a head computed tomography scan to exclude CNS injury (eg, subdural hematoma). (See
         <a class="medical medical_review" href="/z/d/html/13854.html" rel="external">
          "Initial management of trauma in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fever, tachycardia, hypotension, altered mental status, and rigidity
         </strong>
         – In addition to
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         withdrawal, this constellation of signs and symptoms can be found in various medical conditions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neuroleptic malignant syndrome is associated with the use of antipsychotic agents. (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malignant hyperthermia occurs when a susceptible individual is exposed to a volatile anesthetic agent. (See
         <a class="medical medical_review" href="/z/d/html/401.html" rel="external">
          "Malignant hyperthermia: Diagnosis and management of acute crisis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Altered mental status in association with fever or leukocytosis raises concern for meningitis, sepsis, or other infections and warrants a thorough evaluation, often including assessment of the cerebral spinal fluid (CSF). (See
         <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">
          "Clinical features and diagnosis of acute bacterial meningitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">
          "Viral encephalitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">
          "Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autonomic dysreflexia, a manifestation of the loss of coordinated autonomic responses in patients with spinal cord injury above T6, can present with attacks typically triggered by noxious stimuli. (See
         <a class="medical medical_review" href="/z/d/html/4839.html" rel="external">
          "Chronic complications of spinal cord injury and disease", section on 'Autonomic dysreflexia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intrathecal pump and CNS depression
         </strong>
         – Patients with an intrathecal pump are usually receiving either
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         ,
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10333" href="/z/d/drug information/10333.html" rel="external">
          ziconotide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , or cancer chemotherapy (eg,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9992" href="/z/d/drug information/9992.html" rel="external">
          thiotepa
         </a>
         ,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5184.html" rel="external">
          "Treatment of leptomeningeal disease from solid tumors", section on 'Intrathecal therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14248.html" rel="external">
          "Interventional therapies for chronic pain"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2339116104">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H818533400">
         <span class="h2">
          All patients: supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapidly assess and address the patient's airway, breathing, and circulation. In a patient with suspected
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut toxicity, establish intravenous (IV) access and continuous cardiac monitoring. In a patient with tachycardia or hypotension, we administer bolus volumes (10 to 20 mL/kg) of isotonic IV fluids (0.9% sodium chloride or
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          lactated Ringer
         </a>
         solution). An anti-emetic (eg,
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         ) is administered for vomiting. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults", section on 'Supportive care'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">
          "Initial management of the critically ill adult with an unknown overdose", section on 'Systematic evaluation: The "ABCDE" approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3915722826">
         <span class="h2">
          Limited role for gastrointestinal decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest not performing routine gastrointestinal decontamination with activated charcoal (AC) in patients with isolated
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut ingestion since intoxication often improves with supportive care. Administering AC provides no additional benefits but can increase the risk of aspiration and complicate airway management. In a patient who presents within 30 to 60 minutes of a reported large ingestion and is asymptomatic, AC may limit absorption and prevent onset of severe toxicity. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1505634741">
         <span class="h2">
          Toxicity-based management
         </span>
        </p>
        <p class="headingAnchor" id="H639774060">
         <span class="h3">
          CNS depression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with central nervous system (CNS) depression from
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut poisoning recover uneventfully, but many will require tracheal intubation for airway protection or ventilatory support. Administer oxygen as needed. A nasopharyngeal airway (ie, nasal trumpet) may be sufficient to overcome upper airway obstruction from CNS depression and preclude the need for tracheal intubation. End-tidal carbon dioxide (EtCO
         <sub>
          2
         </sub>
         ; ie, capnography) is useful to monitor for hypoventilation. (See
         <a class="medical medical_review" href="/z/d/html/267.html" rel="external">
          "Basic airway management in adults", section on 'Nasopharyngeal airway'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6383.html" rel="external">
          "Basic airway management in children", section on 'Nasopharyngeal airway'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/268.html" rel="external">
          "The decision to intubate", section on 'Is patency or protection of the airway at risk?'
         </a>
         .)
        </p>
        <p>
         In a patient with CNS depression and a low respiratory rate (ie, &lt;12 breaths/minute after stimulation), we suggest a trial of parenteral or intranasal
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         . Naloxone would not be expected to reverse the effects of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut but may improve mental status or respiration if the patient has concomitant opioid intoxication. Tracheal intubation may be required if the respiratory status does not improve following naloxone. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">
          "Opioid intoxication in children and adolescents", section on 'Naloxone'
         </a>
         .)
        </p>
        <p>
         We suggest not administering
         <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">
          flumazenil
         </a>
         to a patient with suspected
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut poisoning. Flumazenil is a nonspecific competitive antagonist of the benzodiazepine receptor on the GABA-A channel. It would not be expected to improve intoxication with these agents and may precipitate benzodiazepine withdrawal if the patient has a benzodiazepine co-ingestion. Its use in somnolent patients with benzodiazepine poisoning is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/314.html" rel="external">
          "Benzodiazepine poisoning", section on 'Role of antidote (flumazenil)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2931995154">
         <span class="h3">
          Seizure
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a patient with a prolonged baclofen- or phenibut-induced seizure (&gt;5 minutes) or recurrent seizures, first-line therapy is benzodiazepines (eg, adults:
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         4 mg IV; children: 0.1 mg/kg IV, maximum dose 4 mg). If additional medications are needed,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         or
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         is preferred to
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         as second-line therapy given their greater efficacy for toxin-induced seizures. (See
         <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">
          "Initial management of the critically ill adult with an unknown overdose", section on '"D": Disability and neurological stabilization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">
          "Convulsive status epilepticus in adults: Management", section on 'In-hospital treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">
          "Management of convulsive status epilepticus in children", section on 'In-hospital treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H605159388">
         <span class="h3">
          Agitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a patient with baclofen- or phenibut-induced agitation that requires pharmacologic sedation, we prefer benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         2 to 4 mg IV or intramuscularly [IM]).
        </p>
        <p>
         A patient who is not adequately sedated following benzodiazepine administration may require tracheal intubation to facilitate escalation of pharmacologic sedation (eg,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">
          "Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Initiating sedative-analgesics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H182027247">
         <span class="h2">
          Patients with kidney impairment
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a patient with severe
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         poisoning (eg, coma) and severe kidney impairment, we suggest extracorporeal removal in addition to supportive care. We define kidney impairment as acute kidney injury stage 2 or 3 using the Kidney Disease: Improving Global Outcomes (KDIGO) or stages III-V chronic kidney disease  (
         <a class="graphic graphic_table graphicRef140950" href="/z/d/graphic/140950.html" rel="external">
          table 6
         </a>
         ). The duration of baclofen toxicity is significantly prolonged in patients with severe kidney impairment, and baclofen is effectively cleared by hemodialysis [
         <a href="#rid19">
          19
         </a>
         ]. We expect that phenibut is also cleared by hemodialysis since it is excreted unchanged in the urine and has a chemical structure similar to baclofen; specific supporting evidence does not exist. (See
         <a class="medical medical_review" href="/z/d/html/325.html" rel="external">
          "Enhanced elimination of poisons", section on 'Extracorporeal removal'
         </a>
         .)
        </p>
        <p>
         There is no standard definition of severe
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut poisoning, but the need for mechanical ventilation for airway protection or respiratory failure is accepted by most experts. The preferred extracorporeal removal modality is intermittent hemodialysis, which should be continued until the patient's clinical status improves. Our recommendations are in agreement with those of the Extracorporeal Treatments in Poisoning (EXTRIP) workgroup [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The evidence for hemodialysis in
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         poisoning is based on cohort studies, case reports, and measured hemodialysis clearance, which is typically &gt;120 mL/min in toxicokinetic studies [
         <a href="#rid19">
          19
         </a>
         ]. The EXTRIP workgroup reviewed published studies and cases of patients with kidney impairment and therapeutic dosing toxicity and found those who received extracorporeal removal had a shorter duration of mental status alteration (51 patients, two versus three days) and hospital length of stay (23 patients, three versus eight days), although the findings did not achieve statistical significance [
         <a href="#rid19">
          19
         </a>
         ]. In patients with kidney impairment, especially those with chronic kidney disease and established dialysis access, the benefit of potentially shortening the duration of toxicity (and preventing complications of prolonged mechanical ventilation) outweighs the risks of hemodialysis.
        </p>
        <p>
         In a patient with
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         toxicity and normal kidney function, hemodialysis has not been found to reduce the duration of mechanical ventilation or improve mortality [
         <a href="#rid19">
          19
         </a>
         ]. Most patients will improve within two to three days with supportive care alone.
        </p>
        <p class="headingAnchor" id="H1011649409">
         <span class="h2">
          Patients with intrathecal overdose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinician who manages the pump should be contacted to reprogram the pump to reduce the dose or temporarily stop the infusion [
         <a href="#rid30">
          30
         </a>
         ]. In addition to supportive care, an optional strategy that has been described is withdrawal of 30 mL cerebrospinal fluid ([CSF]; via catheter access port, lumbar puncture, or lumbar drain) [
         <a href="#rid48">
          48
         </a>
         ]. Since most patients with
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         toxicity recover with access to ventilatory support, CSF aspiration likely has a role limited to patients with life-threatening toxicity not improving with available supportive measures. In patients with suspected baclofen toxicity due to intrathecal administration, extracorporeal removal would not be expected to provide benefit since intrathecal baclofen pumps produce relatively low plasma concentrations [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H560828589">
         <span class="h1">
          DISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who have significant respiratory depression (eg, require mechanical ventilation), hypotension, or have been exposed to a hazardous co-ingestant should be admitted to a critical care setting.
        </p>
        <p>
        </p>
        <p>
         Most patients with an isolated
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut ingestion can be safely discharged or cleared for psychiatric evaluation following an observation period of four to six hours, provided that any concerning symptoms, such as central nervous system (CNS) depression, have resolved. The patient should be able to ambulate safely and without assistance prior to discharge. We admit patients with persistent signs of intoxication beyond six hours to a monitored setting until symptoms resolve.
        </p>
        <p>
         A patient with a suspected self-harm attempt, which is a common reason for
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut ingestion, should be referred for urgent behavioral health evaluation.
        </p>
        <p class="headingAnchor" id="H435021911">
         <span class="h1">
          WITHDRAWAL SYNDROMES
         </span>
        </p>
        <p class="headingAnchor" id="H4126563584">
         <span class="h2">
          Baclofen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain a high degree of suspicion for
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         withdrawal in patients with chronic baclofen use who present with hyperthermia, altered mental status, and increased muscle tone (spasticity or rigidity). The treatment goal of baclofen withdrawal is emergent baclofen administration via the same route as that prior to cessation [
         <a href="#rid49">
          49
         </a>
         ]. While administration of other sedative agents is a helpful temporizing measure, treatment may remain incomplete until baclofen is reinstituted.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral dosing
         </strong>
         – Abrupt cessation of oral
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         causes a potentially life-threatening withdrawal syndrome. Common manifestations are hyperthermia, pruritus, and increased spasticity [
         <a href="#rid50">
          50
         </a>
         ]. Other manifestations can include tachycardia, hypertension, anxiety, insomnia, tremor, visual changes, confusion,
         <strong>
         </strong>
         agitation, psychosis, delusions, hallucinations, and seizures. Untreated rigidity can cause hyperthermia, acidemia, and rhabdomyolysis. Reinstitution of the prior dose of baclofen alleviates withdrawal symptoms and can be followed by a taper if cessation is the goal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intrathecal administration
         </strong>
         – Withdrawal from abrupt cessation of intrathecal
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         is typically more severe compared with oral baclofen withdrawal [
         <a href="#rid51">
          51
         </a>
         ]. Symptoms start within hours to two days. Return of baseline spasticity and pruritus without a rash are commonly reported early symptoms [
         <a href="#rid30">
          30
         </a>
         ]. In addition to symptoms seen with oral withdrawal, intrathecal baclofen withdrawal causes muscle rigidity; without treatment, progressive rigidity can lead to severe hyperthermia, tachycardia, acidemia, rhabdomyolysis, and hypotension. Seizures, dysrhythmias, disseminated intravascular coagulation, multiorgan failure, coma, and death have been reported to occur from intrathecal baclofen withdrawal [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intrathecal
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         withdrawal can occur because of pump malfunction, programming error, battery failure, baclofen refill errors, or catheter migration, kinking, or fracture. The clinician who manages the pump should be contacted to evaluate the pump. (See
         <a class="local">
          'Patients with an intrathecal baclofen pump'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment is to reinstate
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         , ideally with intrathecal baclofen (either via pump or lumbar puncture) at the precessation dose if known; otherwise, 50 mcg baclofen intrathecally improves spasticity in most patients and can be redosed as needed [
         <a href="#rid30">
          30,51
         </a>
         ]. It is often difficult to obtain adequate cerebrospinal fluid (CSF) concentrations with solely oral dosing; high oral doses (eg, ≥240 mg/day) have been required. If intrathecal delivery cannot be promptly reinstated, high-dose oral baclofen combined with intravenous benzodiazepines, barbiturates, or
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (in a patient with a secure airway) can be temporizing measures.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2999369126">
         <span class="h2">
          Phenibut
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abrupt cessation of phenibut use can precipitate a complex withdrawal syndrome similar to
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         withdrawal. Commonly reported symptoms include anxiety and insomnia [
         <a href="#rid12">
          12
         </a>
         ]. Patients may develop nausea, hyperthermia, agitation, visual or auditory hallucinations, delusions, paranoia, tremor, myoclonus, rigidity, catatonia, seizures, and rhabdomyolysis. A case report describes a patient who developed dependence after only 10 days of daily self-treatment of restless leg syndrome; after abruptly stopping use, withdrawal symptoms included nervousness, irritability, palpitations, nausea, and insomnia [
         <a href="#rid52">
          52
         </a>
         ]. Neonatal withdrawal from in-utero exposure to phenibut has also been reported [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Management often requires aggressive treatment since signs and symptoms can be refractory to standard treatment of a sedative-hypnotic withdrawal (eg, benzodiazepines) [
         <a href="#rid12">
          12
         </a>
         ]. In patients with severe phenibut withdrawal, tracheal intubation has been required for airway protection to facilitate adequate sedation and muscle relaxation [
         <a href="#rid14">
          14
         </a>
         ]. In a case report, phenibut withdrawal was successfully managed by gradually substituting 10 mg of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         for each gram of phenibut that the patient had used daily, followed by a taper [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2406880017">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H3168968309">
         <span class="h2">
          Regional poison centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2584874361">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1342586878">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacology
         </strong>
         –
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         and phenibut (GABA-B receptor agonists) are recreationally misused and can accumulate and cause toxicity in patients with kidney impairment. (See
         <a class="local">
          'Pharmacology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features of overdose
         </strong>
         – Common vital sign abnormalities include hypothermia, hypoventilation, hypotension, and bradycardia. Symptoms of mild toxicity include somnolence, nausea, and vomiting. More severe toxicity can include myoclonus, hypotonia, respiratory depression/failure, seizures, and/or coma. Severe
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         toxicity can mimic brain death with loss of brain stem reflexes. Baclofen and phenibut misuse or overdose can produce paradoxical agitation. A summary table to facilitate emergency management is provided  (
         <a class="graphic graphic_table graphicRef143115" href="/z/d/graphic/143115.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical features of overdose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Routine laboratory and diagnostic testing is aimed at excluding other diagnoses and includes serum chemistries, creatinine, complete blood count, serum
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , salicylate, and ethanol concentrations, and ECG. Examine the anterior abdominal wall for the presence of an implanted intrathecal pump and inspect the surrounding tissue for fluid collection (
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         can be infused intrathecally via an implanted pump). In a patient with a fever, in addition to obtaining studies to identify a source of infection (eg, urinalysis, chest radiograph), we also obtain a creatine kinase, liver enzymes, and coagulation studies, as these can be elevated if the patient has a severe withdrawal syndrome. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient with intrathecal
         </strong>
         <strong>
          baclofen
         </strong>
         <strong>
          pump
         </strong>
         – Pump or catheter malfunction can cause either
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         toxicity or withdrawal. The clinician who manages the pump should be contacted for pump interrogation and possibly other testing or reprogramming. (See
         <a class="local">
          'Patients with an intrathecal baclofen pump'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         –
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         or phenibut poisoning is a clinical diagnosis that should be suspected in a somnolent patient with a corroborating history (eg, report of ingestion), who is known to take one of these agents, or who has an implanted intrathecal pump. It should be a diagnosis of exclusion in the absence of clear corroborating history. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – All patients should receive supportive care. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Central nervous system (CNS) depression
         </strong>
         – Most patients with CNS depression from
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut poisoning recover uneventfully, but many will require tracheal intubation and mechanical ventilation. (See
         <a class="local">
          'CNS depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a patient with a low respiratory rate and CNS depression, we administer a trial of parenteral or intranasal
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         . Naloxone may improve mental status or respiration if the patient has concomitant opioid intoxication.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Seizure, agitation
         </strong>
         – In a patient with a prolonged
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         or phenibut-induced seizure (&gt;5 minutes), recurrent seizures, or agitation, first-line therapy is benzodiazepines (eg, adults:
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         4 mg intravenous [IV]; children: 0.1 mg/kg IV, maximum dose 4 mg). (See
         <a class="local">
          'Seizure'
         </a>
         above and
         <a class="local">
          'Agitation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney impairment
         </strong>
         – In a patient with severe
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         poisoning with severe kidney impairment  (
         <a class="graphic graphic_table graphicRef140950" href="/z/d/graphic/140950.html" rel="external">
          table 6
         </a>
         ), we suggest hemodialysis in addition to supportive care (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The prolonged duration of baclofen toxicity with severe kidney impairment can be shortened since it is effectively cleared by hemodialysis. We define severe poisoning as the need for mechanical ventilation for airway protection or respiratory failure. (See
         <a class="local">
          'Patients with kidney impairment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Withdrawal syndromes
         </strong>
         – Abrupt cessation of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         (oral or intrathecal) or phenibut use can cause a withdrawal syndrome that may include anxiety, insomnia, pruritus, hyperthermia, tachycardia, hypertension, confusion, agitation, psychosis, delusions, hallucinations, myoclonus, hypertonia, and seizures. Intrathecal baclofen withdrawal is more likely to be life threatening and cause severe hyperthermia, severe tachycardia, hypotension, rhabdomyolysis, disseminated intravascular coagulation, multiorgan failure, coma, and death. The treatment goal of baclofen withdrawal is emergent baclofen administration via the same route as that prior to cessation. Phenibut withdrawal can be treated with benzodiazepines, baclofen, barbiturates, or
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (if secure airway). (See
         <a class="local">
          'Withdrawal syndromes'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Beuhler MC, et al. 2021 Annual Report of the National Poison Data System© (NPDS) from America's Poison Centers: 39th Annual Report. Clin Toxicol (Phila) 2022; 60:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila) 2021; 59:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila) 2019; 57:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Spyker DA, et al. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila) 2018; 56:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graves JM, Dilley J, Kubsad S, Liebelt E. Notes from the Field: Phenibut Exposures Reported to Poison Centers - United States, 2009-2019. MMWR Morb Mortal Wkly Rep 2020; 69:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gassmann M, Bettler B. Regulation of neuronal GABA(B) receptor functions by subunit composition. Nat Rev Neurosci 2012; 13:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol 2021; 19:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heetla HW, Proost JH, Molmans BH, et al. A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity. Br J Clin Pharmacol 2016; 81:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 2001; 7:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen PA, Ellison RR, Travis JC, et al. Quantity of phenibut in dietary supplements before and after FDA warnings. Clin Toxicol (Phila) 2022; 60:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weleff J, Kovacevich A, Burson J, et al. Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review. J Addict Med 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zvejniece L, Vavers E, Svalbe B, et al. R-phenibut binds to the α2-δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacol Biochem Behav 2015; 137:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosn J Basic Med Sci 2019; 19:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samokhvalov AV, Paton-Gay CL, Balchand K, Rehm J. Phenibut dependence. BMJ Case Rep 2013; 2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal SK, Kriel RL, Cloyd JC, et al. A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers. J Child Neurol 2015; 30:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowalski P, Chmielewska A, Konieczna L, et al. The bioequivalence study of baclofen and lioresal tablets using capillary electrophoresis. Biomed Chromatogr 2004; 18:311.
          </a>
         </li>
         <li class="breakAll">
          OZOBAX (baclofen) [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208193s000lbl.pdf (Accessed on April 24, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Berling I, Lavergne V, et al. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. Kidney Int 2021; 100:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wuis EW, Dirks MJ, Termond EF, et al. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol 1989; 37:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wuis EW, Dirks MJ, Vree TB, Van der Kleijn E. Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses. Pharm Weekbl Sci 1990; 12:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He Y, Brunstrom-Hernandez JE, Thio LL, et al. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. J Pediatr 2014; 164:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faigle JW, Keberle H. The chemistry and kinetics of Lioresal. Postgrad Med J 1972; 48:Suppl 5:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerkin R, Curry SC, Vance MV, et al. First-order elimination kinetics following baclofen overdose. Ann Emerg Med 1986; 15:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlavonou R, Perreault MM, Barrière O, et al. Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations. J Clin Pharmacol 2014; 54:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chauvin KJ, Blake PG, Garg AX, et al. Baclofen has a risk of encephalopathy in older adults receiving dialysis. Kidney Int 2020; 98:979.
          </a>
         </li>
         <li class="breakAll">
          Lioresal intrathecal (baclofen injection) [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020075s037lbl.pdf (Accessed on April 24, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sallerin-Caute B, Lazorthes Y, Monsarrat B, et al. CSF baclofen levels after intrathecal administration in severe spasticity. Eur J Clin Pharmacol 1991; 40:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh NK, Agarwal A, Salazar L, Henkle JQ. Osborn waves in hypothermia induced by baclofen overdose. BMJ Case Rep 2009; 2009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saulino M, Anderson DJ, Doble J, et al. Best Practices for Intrathecal Baclofen Therapy: Troubleshooting. Neuromodulation 2016; 19:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunali Y, Hanimoglu H, Tanriverdi T, et al. Intrathecal baclofen toxicity and deep coma in minutes. J Spinal Cord Med 2006; 29:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nedzlek CD, Michaelis A. An Unusual Presentation of an Uncommon Drug: A Case Report on Phenibut Overdose. Cureus 2022; 14:e23913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung NY, Whyte IM, Isbister GK. Baclofen overdose: defining the spectrum of toxicity. Emerg Med Australas 2006; 18:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sankary S, Canino P, Jackson J. Phenibut overdose. Am J Emerg Med 2017; 35:516.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCabe DJ, Bangh SA, Arens AM, Cole JB. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med 2019; 37:2066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostermann ME, Young B, Sibbald WJ, Nicolle MW. Coma mimicking brain death following baclofen overdose. Intensive Care Med 2000; 26:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muntinga L, Klijn AJ, Noordergraaf GJ. A Severe Baclofen Intoxication Mimicking Post-Hypoxic Encephalopathy: Wait and See! J Emerg Med 2022; 62:e44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koker A, Arslan G, Özden Ö, et al. An intoxication mimicking brain death: baclofen. Acta Neurol Belg 2020; 120:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan R, Hodgman MJ, Kao L, Tormoehlen LM. Baclofen overdose mimicking brain death. Clin Toxicol (Phila) 2012; 50:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller JJ. Baclofen overdose mimicking anoxic encephalopathy: a case report and review of the literature. Ther Adv Drug Saf 2017; 8:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su W, Yegappan C, Carlisle EJ, Clase CM. Reduced level of consciousness from baclofen in people with low kidney function. BMJ 2009; 339:b4559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acosta E, Munguti C. Acute Psychosis Associated with Phenibut Ingestion. Kans J Med 2021; 14:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downes MA, Berling IL, Mostafa A, et al. Acute behavioural disturbance associated with phenibut purchased via an internet supplier. Clin Toxicol (Phila) 2015; 53:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichmuth P, Blanc AL, Tagan D. Unintentional baclofen intoxication in the management of alcohol use disorder. BMJ Case Rep 2015; 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drevin G, Briet M, Ghamrawi S, et al. Baclofen overdose following recreational use in adolescents and young adults: A case report and review of the literature. Forensic Sci Int 2020; 316:110541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipscomb DJ, Meredith TJ. Baclofen overdose. Postgrad Med J 1980; 56:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry HE, Wright RO, Shannon MW, Woolf AD. Baclofen overdose: drug experimentation in a group of adolescents. Pediatrics 1998; 101:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watve SV, Sivan M, Raza WA, Jamil FF. Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord 2012; 50:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romito JW, Turner ER, Rosener JA, et al. Baclofen therapeutics, toxicity, and withdrawal: A narrative review. SAGE Open Med 2021; 9:20503121211022197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alden TD, Lytle RA, Park TS, et al. Intrathecal baclofen withdrawal: a case report and review of the literature. Childs Nerv Syst 2002; 18:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg MI, Hendrickson RG. Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement. J Toxicol Clin Toxicol 2003; 41:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magsalin RM, Khan AY. Withdrawal symptoms after Internet purchase of phenibut (β-phenyl-γ-aminobutyric acid HCl). J Clin Psychopharmacol 2010; 30:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pena F, Manzar S, Dominguez MG. Phenibut withdrawal management in a neonate. Pediatr Neonatol 2022; 63:661.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 141081 Version 8.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36602072" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2021 Annual Report of the National Poison Data System©(NPDS) from America's Poison Centers: 39th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34890263" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31752545" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30576252" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32881852" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Notes from the Field: Phenibut Exposures Reported to Poison Centers - United States, 2009-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22595784" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Regulation of neuronal GABA(B) receptor functions by subunit composition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34417930" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : GABAA receptors: structure, function, pharmacology, and related disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27099877" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11830761" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34550038" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Quantity of phenibut in dietary supplements before and after FDA warnings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36745903" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26234470" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : R-phenibut binds to theα2-δsubunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30501608" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23391959" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Phenibut dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25028414" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15236439" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The bioequivalence study of baclofen and lioresal tablets using capillary electrophoresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15236439" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The bioequivalence study of baclofen and lioresal tablets using capillary electrophoresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34358487" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2792173" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Plasma and urinary excretion kinetics of oral baclofen in healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2336342" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24607242" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4668367" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The chemistry and kinetics of Lioresal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3729110" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : First-order elimination kinetics following baclofen overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24414993" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32450156" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Baclofen has a risk of encephalopathy in older adults receiving dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32450156" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Baclofen has a risk of encephalopathy in older adults receiving dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2050171" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : CSF baclofen levels after intrathecal administration in severe spasticity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21686448" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Osborn waves in hypothermia induced by baclofen overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27434299" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Best Practices for Intrathecal Baclofen Therapy: Troubleshooting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16859228" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intrathecal baclofen toxicity and deep coma in minutes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35530906" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : An Unusual Presentation of an Uncommon Drug: A Case Report on Phenibut Overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16454779" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Baclofen overdose: defining the spectrum of toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27666756" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Phenibut overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30878413" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Phenibut exposures and clinical effects reported to a regional poison center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11030173" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Coma mimicking brain death following baclofen overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35101314" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A Severe Baclofen Intoxication Mimicking Post-Hypoxic Encephalopathy: Wait and See!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30196372" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : An intoxication mimicking brain death: baclofen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22292975" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Baclofen overdose mimicking brain death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28588762" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Baclofen overdose mimicking anoxic encephalopathy: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20044395" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Reduced level of consciousness from baclofen in people with low kidney function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34888004" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Acute Psychosis Associated with Phenibut Ingestion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26114346" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Acute behavioural disturbance associated with phenibut purchased via an internet supplier.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26396128" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Unintentional baclofen intoxication in the management of alcohol use disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33096455" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Baclofen overdose following recreational use in adolescents and young adults: A case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6771749" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Baclofen overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9606233" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Baclofen overdose: drug experimentation in a group of adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22006082" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Management of acute overdose or withdrawal state in intrathecal baclofen therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34158937" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Baclofen therapeutics, toxicity, and withdrawal: A narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12382179" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intrathecal baclofen withdrawal: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12645974" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20841974" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Withdrawal symptoms after Internet purchase of phenibut (β-phenyl-γ-aminobutyric acid HCl).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35927183" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Phenibut withdrawal management in a neonate.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
